Cited by 1,987Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 60 of the 70 references it cites were found in a registry or an index.

The p53 proto-oncogene can act as a suppressor of transformation

Finlay, Cathy A., Hinds, Philip W., Levine, Arnold J.·1989·Cell

Open this paper in CoChat — free account

Abstract

DNA clones of the wild-type p53 proto-oncogene inhibit the ability of E1A plus ras or mutant p53 plus ras-activated oncogenes to transform primary rat embryo fibroblasts. The rare clones of transformed foci that result from E1A plus ras plus wild-type p53 triple transfections all contain the p53 DNA in their genome, but the great majority fail to express the p53 protein. The three cell lines derived from such foci that express p53 all produce mutant p53 proteins with properties similar or identical to transformation-activated p53 proteins. The p53 mutants selected in this fashion (transformation in vitro) resemble the p53 mutants selected in tumors (in vivo). These results suggest that the p53 proto-oncogene can act negatively to block transformation.

Integrity signals

Registry

Crossref · 10.1016/0092-8674(89)90045-7

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,302
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.
Southern, P. J., & Berg, P. R. (1982) · PubMed · Cited by 2,740
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814
Self-citation
SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene
DeCaprio, J. A., Ludlow, J. W., Figge, J., Shew, J.-Y., Huang, C.-M., Lee, W.-H., Marsilio, E., Paucha, E., & Livingston, D. M. (1988) · Cell · doi:10.1016/0092-8674(88)90559-4 · Cited by 1,459
Human Retinoblastoma Susceptibility Gene: Cloning, Identification, and Sequence
Lee, W., Bookstein, R., Hong, F., Young, L.-J., Shew, J., & Lee, E. Y.-H. P. (1987) · Science · doi:10.1126/science.3823889 · Cited by 1,417
Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product
Whyte, P., Buchkovich, K. J., Horowitz, J. M., Friend, S. H., Raybuck, M., Weinberg, R. A., & Harlow, E. (1988) · Nature · doi:10.1038/334124a0 · Cited by 1,403
Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture
Ruley, H. E. (1983) · Nature · doi:10.1038/304602a0 · Cited by 1,248

Show all 70 references

Sorted by citations

A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Down-Regulation of Na+/K+ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
Almilaji, A., Szteyn, K., Fein, E., Pakladok, T., Muñoz, C., Elvira, B., Towhid, S. T., Alesutan, I., Shumilina, E. V., Bock, C. –., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350083 · Cited by 8,700
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Self-citation
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
The p53 tumour suppressor gene
Levine, A. J., Momand, J. A., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,785
Self-citation
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citation
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K. R., Signer, S. H., Davidson, N. E., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,730
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Self-citation
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
G 1 Events and Regulation of Cell Proliferation
Pardee, A. B. (1989) · Science · doi:10.1126/science.2683075 · Cited by 2,182
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Self-citation
Putting p53 in context
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Kuerbitz, S. J., Plunkett, B., Walsh, W., & Kastan, M. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7491 · Cited by 1,837
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Self-citation
Tumor Suppressor Genes
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,765
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S. D., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,742
Identification of a Chromosome 18q Gene that Is Altered in Colorectal Cancers
Fearon, E. R., Cho, K. R., Nigro, J. M., Kern, S. E., Simons, J. W., Ruppert, J. M., Hamilton, S. R., Preisinger, A. C., Thomas, G., Kinzler, K. W., et al. (1990) · Science · doi:10.1126/science.2294591 · Cited by 1,760
Modes of p53 regulation.
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Type 1 Neurofibromatosis Gene: Identification of a Large Transcript Disrupted in Three NF1 Patients
Wallace, M. R., Marchuk, D. A., Andersen, L. B., Letcher, R., Odeh, H. M., Saulino, A. M., Fountain, J. W., Brereton, A., Nicholson, J. M., Mitchell, A. L., et al. (1990) · Science · doi:10.1126/science.2134734 · Cited by 1,478
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.169 · Cited by 1,395
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T. D. (1992) · Cell · doi:10.1016/0092-8674(92)90243-6 · Cited by 1,328
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222
Mutant p53: one name, many proteinsPreprint
Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,290
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210
Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.
Münger, K., Werness, B. A., Dyson, N. J., Phelps, W. C., Harlow, E. E., & Howley, P. M. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08594.x · Cited by 1,204
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M. L., Pass, H. I., Gazdar, A. F., & Minna, J. D. (1989) · Science · doi:10.1126/science.2554494 · Cited by 1,196
Two genetic hits (more or less) to cancer
Knudson, A. G. (2001) · Nature reviews. Cancer · doi:10.1038/35101031 · Cited by 1,122
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A. M., Jarosz, D., Friedman, P. N., Prives, C. L., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,065
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,028
Increased expression of mutant forms of p53 oncogene in primary lung cancer
Iggo, R. D., Bártek, J., Lane, D. P., Gatter, K. C., Harris, A. L., & Bártek, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90801-b · Cited by 1,030
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins
Hinds, P. W., Mittnacht, S., Dulić, V., Arnold, A., Reed, S. I., & Weinberg, R. A. (1992) · Cell · doi:10.1016/0092-8674(92)90249-c · Cited by 998
Self-citation
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
Gannon, J., Greaves, R. F., Iggo, R. D., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 970
Protein-protein interactions: methods for detection and analysis
Phizicky, E. M., & Fields, S. (1995) · Microbiological Reviews · doi:10.1128/mr.59.1.94-123.1995 · Cited by 977
Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression
Kern, S. E., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K. W., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Self-citation
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Gaïdano, G., Ballerini, P. F., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., MAGRATH, I. T., Knowles, D., & Dalla‐Favera, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5413 · Cited by 884
Identification of p53 Gene Mutations in Bladder Cancers and Urine Samples
Sidransky, D., von Eschenbach, A., Tsai, Y., Jones, P. A., Summerhayes, I. C., Marshall, F. F., Paul, M., Green, P., Hamilton, S. R., Frost, P., et al. (1991) · Science · doi:10.1126/science.2024123 · Cited by 875
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.Preprint
Debbas, M. E., & White, E. (1993) · Genes & Development · doi:10.1101/gad.7.4.546 · Cited by 866
The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.
Scheffner, M., Münger, K., Byrne, J. C., & Howley, P. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5523 · Cited by 850
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.
Shaw, P. H., Bovey, R., Tardy, S., Sahli, R., Sordat, B., & Costa, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4495 · Cited by 846
Human papillomaviruses in the pathogenesis of anogenital cancer
Hausen, H. Z. (1991) · Virology · doi:10.1016/0042-6822(91)90816-t · Cited by 847
p53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 876
Self-citation
p53: oncogene or anti-oncogene?Preprint
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 796
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Viruses in Human Cancers
Hausen, H. Z. (1991) · Science · doi:10.1126/science.1659743 · Cited by 786
p53 Functions as a Cell Cycle Control Protein in Osteosarcomas
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M. C., Bressac, B., Öztürk, M., Baker, S. J., Vogelstein, B., et al. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 775
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53
Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769
Cooperation between oncogenes
Hunter, T. R. (1991) · Cell · doi:10.1016/0092-8674(91)90637-e · Cited by 758
Tumor suppressor genes
Marshall, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90641-b · Cited by 752
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 836
Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression
Owen‐Schaub, L. B., Zhang, W. K., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A., Zhang, W., Kruzel, E., et al. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3032 · Cited by 740
Wild-type p53 can inhibit oncogene-mediated focus formation.
Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 687
Mapping of the p53 and mdm-2 Interaction Domains
Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 700
Self-citation
Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.Preprint
Lowe, S. W., & Ruley, H. E. (1993) · Genes & Development · doi:10.1101/gad.7.4.535 · Cited by 668
Twenty years of p53 research: structural and functional aspects of the p53 protein
May, P., & May, E. (1999) · Oncogene · doi:10.1038/sj.onc.1203285 · Cited by 682
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Preprint
Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652
Self-citation
Analysis of p53-regulated gene expression patterns using oligonucleotide arraysPreprint
Zhao, R., Gish, K., Murphy, M. E., Yin, Y., Notterman, D. A., Hoffman, W. H., Tom, E., Mack, D. H., & Levine, A. J. (2000) · Genes & Development · doi:10.1101/gad.14.8.981 · Cited by 632
Self-citation
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 620
Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation
Milner, J., & Medcalf, E. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
Moll, U. M., RIOU, G. F., & Levine, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7262 · Cited by 572
Self-citation
An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor
Haber, D. A., Buckler, A., Glaser, T. M., Call, K. M., Pelletier, J., Sohn, R., Douglass, E. C., & Housman, D. E. (1990) · Cell · doi:10.1016/0092-8674(90)90690-g · Cited by 571
p53 mutations increase resistance to ionizing radiation.
Lee, J. M., & Bernstein, A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5742 · Cited by 570
Cloning and Expression of the cDNA for E6-AP, a Protein that Mediates the Interaction of the Human Papillomavirus E6 Oncoprotein with p53
Huibregtse, J. M., Scheffner, M., & Howley, P. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.2.775 · Cited by 553
Induction of apoptosis in HeLa cells by trans-activation-deficient p53.Preprint
Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H., & Oren, M. (1995) · Genes & Development · doi:10.1101/gad.9.17.2170 · Cited by 547
Detection of p53 Gene Mutations in Human Brain Tumors by Single-strand Conformation Polymorphism Analysis of Polymerase Chain Reaction Products
Mashiyama, S., Kayama, T., Katakura, R., Yoshimoto, T., Murakami, Y., Sekiya, T., & Hayashi, K. (1991) · Springer eBooks · doi:10.1007/978-4-431-68150-2_41 · Cited by 538
An immunochemical analysis of the human nuclear phosphoprotein p53
Vojtěšek, B., Bártek, J., Midgley, C., & Lane, D. P. (1992) · Journal of Immunological Methods · doi:10.1016/0022-1759(92)90122-a · Cited by 531
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.Preprint
Martinez, J., Georgoff, I., Martinez, J., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.2.151 · Cited by 528
Self-citation
Genetic Mechanisms of Tumor Suppression by the Human p53 Gene
Chen, P., Chen, Y., Bookstein, R., & Lee, W. (1990) · Science · doi:10.1126/science.2274789 · Cited by 518
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 538
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation
Crook, T., Vousden, K. H., & TIDY, J. A. (1991) · Cell · doi:10.1016/0092-8674(91)90529-8 · Cited by 503
Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer.
Sato, T., Tanigami, A., Yamakawa, K., Akiyama, F., Kasumi, F., Sakamoto, G., & Nakamura, Y. (1990) · PubMed · Cited by 501
p53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 483
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.
Mercer, W. E., Shields, M. T., Amin, M., Sauvé, G. J., Appella, E., Romano, J., & Ullrich, S. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.16.6166 · Cited by 477
Tumor Suppressor Genes: The Puzzle and the Promise
Sager, R. (1989) · Science · doi:10.1126/science.2574499 · Cited by 474
Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke‐Pearson, D. L., Iglehart, J. D., Bast, R. C., & Berchuck, A. (1991) · PubMed · Cited by 465
p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts.
Harvey, D. M., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.12b.2375 · Cited by 453
Self-citation
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors
Kemp, C. J., Donehower, L. A., Bradley, A., & Balmain, A. (1993) · Cell · doi:10.1016/0092-8674(93)90461-x · Cited by 456
p53 Research: The Past Thirty Years and the Next Thirty YearsPreprint
Lane, D. P., & Levine, A. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 469
Self-citation
Wild-type p53 can down-modulate the activity of various promoters.
Ginsberg, D., Mechta‐Grigoriou, F., Yaniv, M., & Oren, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9979 · Cited by 434
The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis
Levine, A. J., Perry, M. E., Chang, A., Silver, A., Dittmer, D. P., Wu, M. C., & Welsh, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.76 · Cited by 418
Self-citation
Abnormal structure and expression of p53 gene in human hepatocellular carcinoma.
Paillerets, B. B., Galvin, K. M., Liang, T. J., Isselbacher, K. J., Wands, J. R., & Öztürk, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1973 · Cited by 415
A comparison of the biological activities of wild‐type and mutant p53
Zambetti, G. P., & Levine, A. J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344485 · Cited by 410
Self-citation
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 408
Self-citation
Viruses associated with human cancer
McLaughlin-Drubin, M. E., & Münger, K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.12.005 · Cited by 422
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Sanada, M., Suzuki, T., Shih, L., Otsu, M., Kato, M., Yamazaki, S., Tamura, A., Honda, H., Sakata‐Yanagimoto, M., Kumano, K., et al. (2009) · Nature · doi:10.1038/nature08240 · Cited by 401
Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis.
Menon, A. G., Anderson, K. M., Riccardi, V. M., Chung, R. Y., Whaley, J. M., Yandell, D. W., Farmer, G. E., Freiman, R. N., Lee, J. K., & Li, F. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5435 · Cited by 396
Localization of the E6-AP Regions That Direct Human Papillomavirus E6 Binding, Association with p53, and Ubiquitination of Associated Proteins
Huibregtse, J. M., Scheffner, M., & Howley, P. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.8.4918 · Cited by 395
High Incidence of Lung, Bone, and Lymphoid Tumors in Transgenic Mice Overexpressing Mutant Alleles of the p53 Oncogene
Lavigueur, A., Maltby, V., Mock, D., Rossant, J., Pawson, T. J., & Bernstein, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982 · Cited by 393
Uncovering the role of p53 splice variants in human malignancy: a clinical perspective
Bourdon, J., Surget, S., & Khoury, M. P. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s53876 · Cited by 399
Defining the molecular mechanisms of human cell immortalization
Shay, J. W., Wright, W. E., & Werbin, H. (1991) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(91)90003-4 · Cited by 382

Authors: Finlay, C. A., Hinds, P. W., & Levine, A. J.
Affiliations: Princeton University (US)
ORCID: Hinds, Philip W.
Levine, Arnold J.
Venue: Cell
Publisher: Elsevier BV
Published: 1989-06
Volume: 57
Issue: 7
Pages: 1083-1093
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/0092-8674(89)90045-7
OpenAlex: W2163565167
Cited by: 1,987
References: 70
Citations by year: 2026: 14 · 2025: 12 · 2024: 25 · 2023: 27 · 2022: 20 · 2021: 34 · 2020: 37 · 2019: 31 · 2018: 29 · 2017: 29 · 2016: 28 · 2015: 12 · 2014: 28 · 2013: 26 · 2012: 38
FWCI: 79.38
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P01CA041086, P01-CA41086-03)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: tumor suppressor, oncogenic transformation, adenovirus E1A, oncogenic Ras, mutant p53, p53 expression, rat embryo fibroblasts, transformed foci, tumor suppressor function
MeSH terms: Animals, Antigens, Polyomavirus Transforming, Cell Line, Cell Transformation, Neoplastic, Cells, Cultured, Gene Expression Regulation, Neoplasm Proteins, Oncogene Proteins, Viral, Phosphoproteins, Proto-Oncogene Proteins, Genes, ras, Transfection, Tumor Suppressor Protein p53, Adenovirus Early Proteins, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The p53 proto-oncogene can act as a suppressor of transformation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks